Last reviewed · How we verify
NCT00728390
A Safety And Efficacy Study Of The Combination Of Oral PF-00299804 And Intravenous CP-751,871 Given Every 3 Weeks
Phase 1 trial testing PF-00299804 in Carcinoma, Non-Small Cell in 74 participants. Completed in 29 January 2013.
9 August 2011
Quick facts
| Lead sponsor | Pfizer |
|---|---|
| Phase | Phase 1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 74 |
| Start date | 15 December 2008 |
| Primary completion | 9 August 2011 |
| Estimated completion | 29 January 2013 |
| Sites | 5 locations across France, United States, Spain |
Drugs / interventions tested
- PF-00299804 — full drug profile →
Conditions studied
- Carcinoma, Non-Small Cell — all drugs for Carcinoma, Non-Small Cell →
- Neoplasm Metastasis — all drugs for Neoplasm Metastasis →
Sponsor
Pfizer — full company profile →
Who can join
18 and older, any sex, with Carcinoma, Non-Small Cell or Neoplasm Metastasis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study will explore the combination of the oral drug PF-00299804 and intravenous CP-751,871 in patients with advanced solid tumor. Each of these drugs have been given separately to patients in prior studies, and this study is to establish the safety and efficacy of the combination.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Nonsmall cell lung cancer therapy: insight into multitargeted small-molecule growth factor receptor inhibitors.
Roy M, Luo YH, Ye M, Liu J. · · 2013 · cited 16× · PMID 23936861 · DOI 10.1155/2013/964743 -
Novel small molecule EGFR inhibitors as candidate drugs in non-small cell lung cancer.
Berardi R, Santoni M, Morgese F, Ballatore Z, et al · · 2013 · cited 16× · PMID 23723712 · DOI 10.2147/ott.s28155
Verify or expand the search:
- PubMed search for NCT00728390
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of PF-00299804
Trials testing the same drug.
- NCT01000025 — PF-00299804 in Stage IIIB or Stage IV Non-Small Cell Lung Cancer Not Responding to Standard Therapy for Advanced or Meta · Phase 3 · completed
- NCT00768664 — Open-Label Trial Of Oral PF-00299804 By Continuous Dosing In Patients With Recurrent Or Metastatic Head And Neck Squamou · Phase 2 · completed
- NCT00548093 — PF-00299804 As A Single Agent, In Patients With Advanced Non-Small Cell Lung Cancer Who Have Failed Chemotherapy And Erl · Phase 2 · completed
- NCT00553254 — Trial Of PF-00299804 In Patients With Advanced Refractory Lung Cancer · Phase 2 · completed
- NCT00225121 — Study To Evaluate The Safety, Pharmacokinetics, And Pharmacodynamics Of PF-00299804 In Patients With Advanced Solid Tumo · Phase 1 · completed
Other Pfizer trials
Trials by the same sponsor.
- NCT04982848 — Korea Post Marketing Surveillance (PMS) Study of Talzenna® · not yet recruiting
- NCT06873191 — A Study to Learn More About Tukysa Once it is Out in the Korean Market · not yet recruiting
- NCT07497854 — A Study to Learn About the Study Medicine NURTEC® ODT 75 mg After it is Released Into the Markets in Korea · not yet recruiting
- NCT06507904 — A Study to Learn How Different Preparations of Osivelotor Taste and Enter the Blood With Food or Liquids or With an Anta · Phase 1 · not yet recruiting
- NCT06864585 — A Study to Learn About the Study Medicine - Zavicefta in Patients With Sepsis or Loss of Kidney Function in Japan · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT00728390 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Pfizer
- Last refreshed: 22 April 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00728390.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing